Literature DB >> 23684828

Post-vaccination serological test results of infants at risk of perinatal transmission of hepatitis B using an intensified follow-up programme in a London centre.

Cheuk Y W Tong1, Carol Robson, Yin Wu, Rozanna Issa, Timothy Watts, Mark Wilkinson, Terry Wong, Ann Lorek.   

Abstract

Immunisation of infants born to hepatitis B virus (HBV) infected mothers is an important public health measure to prevent mother-to-child transmission of HBV. Post-vaccination serological tests (PVST) inform the success of the infant HBV immunisation programme and identify infected infants. Previous studies suggested that the rates of PVST in the UK programme were unsatisfactory. We introduced an intensified local follow-up programme and offered an earlier PVST 2-3 months after the third vaccination at age 4-5 months. Of 219 infants born between 2009 and 2011, 193 infants (88.1%) had at least one PVST: 145 (66.2%) early; 94 (42.9%) standard; 46 (21.0%) both and 26 (11.9%) never tested. Twenty-four infants were identified as high risk for mother-to-child transmission according to national criteria and received both hepatitis B immunoglobulin (HBIG) and hepatitis B vaccine at birth. These infants had a significantly lower hepatitis B surface antibody (anti-HBs) levels at early PVST compared to the lower risk group who received hepatitis B vaccine only (median of 59 vs. 376 mIU/ml, P=0.006). None of the infants tested were infected with hepatitis B. This study illustrates that the rate of PVST can be improved by using an intensified follow-up programme offering an early PVST. The significantly lower anti-HBs levels in the HBIG subgroup is of concern as this group of infants is already at higher risk for acquiring HBV infection. Infants with poor antibody responses can be identified by an early PVST and offered a timely extra booster dose.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23684828     DOI: 10.1016/j.vaccine.2013.04.083

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  4 in total

Review 1.  Comparative efficacy of antiviral therapy in preventing vertical transmission of hepatitis B: a network meta-analysis.

Authors:  Basile Njei; Neil Gupta; Oforbuike Ewelukwa; Ivo Ditah; Munoh Foma; Joseph K Lim
Journal:  Liver Int       Date:  2015-10-01       Impact factor: 5.828

2.  Effectiveness of prevention of mother-to-child transmission practice in three provinces of Southern China.

Authors:  Fuzhen Wang; Hui Zheng; Guomin Zhang; Zhengrong Ding; Fangjun Li; Ge Zhong; Yuansheng Chen; Yuanxi Jia; Ning Miao; Zhenhua Wu; Xiaojin Sun; Li Li; Xiaofeng Liang; Fuqiang Cui
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  Compliance among infants exposed to hepatitis B virus in a post-vaccination serological testing program in four provinces in China.

Authors:  Hui Zheng; Guo-Min Zhang; Po-Lin Chan; Fu-Zhen Wang; Lance Everett Rodewald; Ning Miao; Xiao-Jin Sun; Zun-Dong Yin; Jeffrey Edwards; Hua-Qing Wang
Journal:  Infect Dis Poverty       Date:  2019-07-04       Impact factor: 4.520

4.  Comparing HBV Viral Load in Serum, Cerumen, and Saliva and Correlation With HBeAg Serum Status in Patients With Chronic Hepatitis B Infection.

Authors:  Elaheh Gholami Parizad; Eskandar Gholami Parizad; Afra Khosravi; Mansour Amraei; Azar Valizadeh; Abdoullah Davoudian
Journal:  Hepat Mon       Date:  2016-04-27       Impact factor: 0.660

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.